ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
USA - NASDAQ:ADMA - US0008991046 - Common Stock
15.07 USD
+0.35 (+2.38%)
Overall ADMA gets a fundamental rating of 6 out of 10. We evaluated ADMA against 534 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make ADMA suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA reported 4 times negative net income.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
ADMA has a better Return On Assets (37.42%) than 98.88% of its industry peers.
With an excellent Return On Equity value of 52.45%, ADMA belongs to the best of the industry, outperforming 98.69% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 25.43%, ADMA belongs to the top of the industry, outperforming 98.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROIC | 25.43% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ADMA (44.06%) is better than 98.50% of its industry peers.
The Operating Margin of ADMA (32.82%) is better than 97.38% of its industry peers.
The Gross Margin of ADMA (53.00%) is better than 76.03% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
ADMA has an Altman-Z score of 15.01. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.01, ADMA belongs to the best of the industry, outperforming 87.08% of the companies in the same industry.
ADMA has a debt to FCF ratio of 1.12. This is a very positive value and a sign of high solvency as it would only need 1.12 years to pay back of all of its debts.
ADMA has a better Debt to FCF ratio (1.12) than 94.19% of its industry peers.
ADMA has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.18, ADMA is doing worse than 67.60% of the companies in the same industry.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Altman-Z | 15.01 |
ROIC/WACC2.69
WACC9.44%
2.3 Liquidity
A Current Ratio of 5.33 indicates that ADMA has no problem at all paying its short term obligations.
The Current ratio of ADMA (5.33) is comparable to the rest of the industry.
ADMA has a Quick Ratio of 2.78. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA's Quick ratio of 2.78 is on the low side compared to the rest of the industry. ADMA is outperformed by 64.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 285.71%, which is quite impressive.
The Revenue has grown by 43.58% in the past year. This is a very strong growth!
The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)43.58%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
3.2 Future
The Earnings Per Share is expected to grow by 32.01% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.46% on average over the next years. This is a very strong growth
EPS Next Y15.6%
EPS Next 2Y34.24%
EPS Next 3Y36.01%
EPS Next 5Y32.01%
Revenue Next Year19.9%
Revenue Next 2Y22.93%
Revenue Next 3Y25%
Revenue Next 5Y22.46%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 27.91, the valuation of ADMA can be described as expensive.
Based on the Price/Earnings ratio, ADMA is valued cheaper than 94.19% of the companies in the same industry.
ADMA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 16.73 indicates a correct valuation of ADMA.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.01% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, ADMA is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.91 | ||
| Fwd PE | 16.73 |
4.2 Price Multiples
ADMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ADMA is cheaper than 93.82% of the companies in the same industry.
92.70% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.81 | ||
| EV/EBITDA | 21.37 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 36.01% in the coming years.
PEG (NY)1.79
PEG (5Y)N/A
EPS Next 2Y34.24%
EPS Next 3Y36.01%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ADMA (10/22/2025, 11:37:05 AM)
15.07
+0.35 (+2.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change-0.37%
Ins Owners2.35%
Ins Owner Change-0.76%
Market Cap3.60B
Revenue(TTM)474.17M
Net Income(TTM)208.93M
Analysts82
Price Target29.64 (96.68%)
Short Float %6.87%
Short Ratio4.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)0%
PT rev (3m)-1.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-6.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.91 | ||
| Fwd PE | 16.73 | ||
| P/S | 7.58 | ||
| P/FCF | 54.81 | ||
| P/OCF | 46.88 | ||
| P/B | 9.03 | ||
| P/tB | 9.12 | ||
| EV/EBITDA | 21.37 |
EPS(TTM)0.54
EY3.58%
EPS(NY)0.9
Fwd EY5.98%
FCF(TTM)0.27
FCFY1.82%
OCF(TTM)0.32
OCFY2.13%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.79
PEG (5Y)N/A
Graham Number4.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROCE | 32.19% | ||
| ROIC | 25.43% | ||
| ROICexc | 31.27% | ||
| ROICexgc | 31.6% | ||
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% | ||
| FCFM | 13.84% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 140.25% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | 13.21 | ||
| Cash Conversion | 46.9% | ||
| Profit Quality | 31.4% | ||
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 15.01 |
F-Score5
WACC9.44%
ROIC/WACC2.69
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y15.6%
EPS Next 2Y34.24%
EPS Next 3Y36.01%
EPS Next 5Y32.01%
Revenue 1Y (TTM)43.58%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
Revenue Next Year19.9%
Revenue Next 2Y22.93%
Revenue Next 3Y25%
Revenue Next 5Y22.46%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.1%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A